Technical Analysis for ATNF - 180 Life Sciences Corp.

Grade Last Price % Change Price Change
C 3.74 -4.59% -0.18
ATNF closed down 4.59 percent on Friday, November 1, 2024, on 6 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: Nov 7
*** please verify all earnings dates ***
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Doji - Bullish? Reversal 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
MACD Bearish Signal Line Cross Bearish -4.59%
Narrow Range Bar Range Contraction -4.59%
Wide Bands Range Expansion -4.59%
Oversold Stochastic Weakness -4.59%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 17 hours ago
Down 5% about 20 hours ago
Down 3% about 20 hours ago
Fell Below Previous Day's Low about 20 hours ago
Down 2 % about 20 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease – inflammation. The Company is driving groundbreaking study into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The Company’s primary platform is a novel program to treat fibrosis using anti-TNF, with its lead program in phase 2b/3 clinical trials.
Classification

Sector: Industrials
Industry: Conglomerates
Keywords: Biotechnology Clinical Medicine Disease Immunology Pain Inflammation Inflammatory Diseases Cytokine Fibrosis Human Physiology Tumor Necrosis Factor Animal Physiology

Is ATNF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 17.75
52 Week Low 1.16
Average Volume 2,491,256
200-Day Moving Average 2.46
50-Day Moving Average 2.45
20-Day Moving Average 3.38
10-Day Moving Average 4.23
Average True Range 1.12
RSI (14) 54.34
ADX 48.36
+DI 62.98
-DI 17.27
Chandelier Exit (Long, 3 ATRs) 14.39
Chandelier Exit (Short, 3 ATRs) 4.52
Upper Bollinger Bands 6.56
Lower Bollinger Band 0.20
Percent B (%b) 0.56
BandWidth 188.29
MACD Line 0.56
MACD Signal Line 0.61
MACD Histogram -0.0498
Fundamentals Value
Market Cap 37.99 Million
Num Shares 10.2 Million
EPS -14.20
Price-to-Earnings (P/E) Ratio -0.26
Price-to-Sales 0.00
Price-to-Book 0.36
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.30
Resistance 3 (R3) 4.32 4.15 4.20
Resistance 2 (R2) 4.15 4.01 4.14 4.17
Resistance 1 (R1) 3.94 3.92 3.86 3.93 4.14
Pivot Point 3.78 3.78 3.74 3.77 3.78
Support 1 (S1) 3.57 3.64 3.49 3.55 3.34
Support 2 (S2) 3.41 3.55 3.40 3.31
Support 3 (S3) 3.20 3.41 3.28
Support 4 (S4) 3.18